/>iIn This Issue
This China Newsletter provides an overview of key Q1 2025 developments in the following areas:
| 1. | Antitrust |
- China Unveils Anti-Monopoly Guidelines for Pharmaceutical Sector
| 2. | Compliance |
- China Formally Finalizes First Anti-Corruption Guidelines for the Health Care and Life Sciences Industry
| 3. | Corporate |
- China Streamlines Company Registration: Key Changes Effective February 2025
| 4. | Data Privacy & Cybersecurity |
- China Issues Personal Information Compliance Audit Rule
- China Issues Regulation for Facial Recognition Technology Applications
- China Issues Measures for Labeling AI-Generated and Synthetic Content
| 5. | Foreign Investment |
- China Publishes 2025 Action Plan for Stabilizing Foreign Investment
| 6. | International Trade |
- China Promulgates Regulations for Implementing Anti-Foreign Sanctions Law
